SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells

Molecular Cancer Research

Volumn 9, Issue 7, 2011, Pages 889-900

  Shultz, Jacqueline C ^a   Goehe, Rachel W ^a   Murudkar, Charuta S ^a   Wijesinghe, Dayanjan S ^a   Mayton, Eric K ^a   Massiello, Autumn ^a   Hawkins, Amy J ^b   Mukerjee, Prabhat ^a   Pinkerman, Ryan L ^e   Park, Margaret A ^a   Chalfant, Charles E ^a,c,d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE 9; CASPASE 9B; CIS ACTING ELEMENT; CISPLATIN; DAUNORUBICIN; ERLOTINIB; MESSENGER RNA; PACLITAXEL; SRSF1 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENHANCER REGION; EXON; GENE CASSETTE; HUMAN; HUMAN CELL; IC 50; INTRON; LUNG NON SMALL CELL CANCER; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; RNA SEQUENCE;

ALTERNATIVE SPLICING; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 9; CELL LINE, TUMOR; CISPLATIN; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENHANCER ELEMENTS, GENETIC; HELA CELLS; HUMANS; INTRONS; LUNG DISEASES; NUCLEAR PROTEINS; PACLITAXEL; QUINAZOLINES; RNA PRECURSORS; RNA SPLICE SITES; RNA, ANTISENSE; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS;

EID: 79960681326     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0061     Document Type: Article

References (30)

1. Quintans J, Kilkus J, McShan CL, Gottschalk AR, Dawson G. Ceramide mediates the apoptotic response of WEHI 231 cells to anti-immunoglobulin, corticosteroids and irradiation. Biochem Biophys Res Commun 1994;202:710-4.
2. Okazaki T, Bielawska A, Bell RM, Hannun YA. Role of ceramide as a lipid mediator of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J Biol Chem 1990;265:15823-31.
3. Liscovitch M. Crosstalk among multiple signal-activated phospholipases. Trends Biochem Sci 1992;17:393-9.
4. Kim MY, Linardic C, Obeid L, Hannun Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. J Biol Chem 1991;266:484-9. (Pubitemid 21906148)
5. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 1994;269:3125-8. (Pubitemid 24237615)
6. Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, et al. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med 1994;180:1547-52. (Pubitemid 24289629)
7. Ballou LR, Chao CP, Holness MA, Barker SC, Raghow R. Interleukin-1- mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J Biol Chem 1992;267:20044-50.
8. Chalfant CE, Kishikawa K, Mumby MC, Kamibayashi C, Bielawska A, Hannun YA. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem 1999;274:20313-7.
9. Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA. Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 1993;268:15523-30. (Pubitemid 23222045)
10. Law B, Rossie S. The dimeric and catalytic subunit forms of protein phosphatase 2A from rat brain are stimulated by C2-ceramide. J Biol Chem 1995;270:12808-13.
11. Wolff RA, Dobrowsky RT, Bielawska A, Obeid LM, Hannun YA. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J Biol Chem 1994;269:19605-9. (Pubitemid 24233493)
12. Mermoud JE, Cohen PTW, Lamond AI. Regulation of mammalian spliceosome assembly by a protein-phosphorylation mechanism. EMBO J 1994;13:5679-88. (Pubitemid 24363036)
13. Chalfant CE, Ogretmen B, Galadari S, Kroesen BJ, Pettus BJ, Hannun YA. FAS activation induces dephosphorylation of SR proteins; dependence on the de novo generation of ceramide and activation of protein phosphatase 1. J Biol Chem 2001;276:44848-55.
14. Chalfant CE, Rathman K, Pinkerman RL, Wood RE, Obeid LM, Ogretmen B, et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 2002;277:12587-95. (Pubitemid 34952617)
15. Massiello A, Chalfant CE. SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA and is required for ceramide-responsiveness. J Lipid Res 2006;47:892-7. (Pubitemid 43764686)
16. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005;19:1-13. (Pubitemid 40884653)
17. Seol DW, Billiar TR. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J Biol Chem 1999;274:2072-6.
18. Srinivasula SM, Ahmad M, Guo Y, Zhan Y, Lazebnik Y, Fernandes-Alnemri T, et al. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Res 1999;59:999-1002. (Pubitemid 29135957)
19. Shultz JC, Goehe RW, Wijesinghe DS, Murudkar C, Hawkins AJ, Shay JW, et al. Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res 2010;70:9185-96.
20. Goehe RW, Shultz JC, Murudkar C, Usanovic S, Lamour NF, Massey DH, et al. hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. J Clin Invest 2010;120:3923-39.
21. Siebert PD, Larrick JW. Competitive PCR. Nature 1992;359:557-8.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
23. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003;31:3568-71. (Pubitemid 37442199)
24. Koscielny G, Le Texier V, Gopalakrishnan C, Kumanduri V, Riethoven JJ, Nardone F, et al. ASTD: the alternative splicing and transcript diversity database. Genomics 2009;93:213-20.
25. Joseph B, Lewensohn R, Zhivotovsky B. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. Ann N Y Acad Sci 2000;926:204-16. (Pubitemid 32050157)
26. Joseph B, Ekedahl J, Lewensohn R, Marchetti P, Formstecher P, Zhivotovsky B. Defective caspase-3 relocalization in non-small cell lung carcinoma. Oncogene 2001;20:2877-88. (Pubitemid 33027755)
27. Gallego MA, Ballot C, Kluza J, Hajji N, Martoriati A, Castéra L, et al. Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway. Oncogene 2008;27:1981-92. (Pubitemid 351442733)
28. Landriscina M, Maddalena F, Fabiano A, Piscazzi A, La Macchia O, Cignarelli M. Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. Anticancer Res 2010;30:473-80.
29. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007;14:185-93. (Pubitemid 46355578)
30. Moore MJ, Wang Q, Kennedy CJ, Silver PA. An alternative splicing network links cell-cycle control to apoptosis. Cell 2010;142:625-36.